A Medical Device Daily
Optherion, (New Haven), a developer of molecular diagnostics and treatments for dry and wet Age-related Macular Degeneration (AMD) and other chronic diseases involving the alternative complement system, reported that the Canadian Patent Office has granted patents 2,363,503 and 2,407,715.
The claims of the issued patents provides protection for diagnostic tests to determine the predisposition to AMD by screening for genetic modifications in several genes including complement factor H, complement factor B, complement factor 2 and complement factor 3, amongst others. Optherion has an exclusive worldwide license to these Canadian patents and corresponding patents and applications from the University of Iowa Research Foundation (Iowa City).
Colin Foster, president/CEO of Optherion, said, "With these and other patents pending, licensed from almost a dozen universities, we are well positioned to exclusively offer a range of predictive and prognostic diagnostic tests to healthcare professionals treating patients with AMD and other diseases of the alternative complement system."
Optherion is developing a genetic test for AMD and said it is pursuing commercialization discussions with North American and international providers.